Integrating the Latest Evidence on Immune Checkpoint Inhibitors Into the Management of Advanced Non-Small Cell Lung Cancer
December 15, 2022
December 15, 2023
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Postgraduate Institute for Medicine and RME Collaborative.
This online program is recorded content from the live session at Oncology Congress and co-supported by independent medical education grants from AbbVie, Inc.; Astellas; AstraZeneca Pharmaceuticals; Bayer HealthCare Pharmaceuticals, Inc.; Eisai, Inc.; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; and Seagen. This activity is supported independent medical education grants from Eisai, Inc.; Merck Sharp & Dohme, LLC, a subsidiary of Merck & Co., Inc.; and Regeneron Pharmaceuticals, Inc. and Sanofi.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Rural counties in the US face a higher incidence of lung cancer than urban areas and also have higher rates of cancer-related mortality and other negative treatment outcomes. These statistics underscore the need for increased education among oncology clinicians in order to improve care and outcomes for these patient populations. In this activity, expert faculty will discuss the latest advances in testing and treatment of advanced non-small cell lung cancer (NSCLC) and current guideline recommendations surrounding immunotherapy. Strategies for reducing disparities in care access and treatment for NSCLC in rural and underserved settings will also be discussed.
This enduring activity is a recorded session from Oncology Congress that took place on September 24, 2022.
Upon completion of this activity, participants should be better able to:
- Apply biomarker testing results to guide treatment decisions for NSCLC
- Differentiate treatment options for advanced NSCLC based on clinical safety and efficacy data
- Integrate clinical evidence and current guideline recommendations on immunotherapies into treatment plans for patients with advanced NSCLC
- Implement interprofessional strategies for reducing disparities in care access and treatment for NSCLC in rural and underserved settings
Mark G. Kris, MD
Professor of Medicine
Weill Cornell Medical College
Attending Physician, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Sucharu (Chris) Prakash, MD
Oncologist & Regional Medical Director
Texas Oncology – Paris
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
Disclosures of Conflicts of Interest
Postgraduate Institute for Medicine and RME Collaborative adhere to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Postgraduate Institute for Medicine requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies (commercial interests). All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to Postgraduate Institute for Medicine policy. Postgraduate Institute for Medicine is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Mark G. Kris, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from AstraZeneca Pharmaceuticals and Pfizer, Inc.; consultant/advisory board member for AstraZeneca Pharmaceuticals, BerGenBio, Daiichi Sankyo, Janssen Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Sanofi; and financial support for editorial services from Genentech, Inc.
Sucharu (Chris) Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.
Planners, Managers, and Reviewer
The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.
Instructions for Participation and Credit
This activity is offered at no cost to participants. To receive CME credit, participants must:
- Read the CME/CE information, including learning objectives and disclosure statements..
- Complete the pre-test.
- View the online activity.
- Complete the post-test and evaluation form.
A post-test score of 75% or higher is required to obtain credit. Your certificate will be made available for immediate download.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
©RME Collaborative, a division of Talem Health, LLC 2022. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.
There is no fee for this educational activity.
For general information or questions about this activity, please contact RME Collaborative at 800-913-9370 or email@example.com.
For questions regarding the certification of this activity, please contact Postgraduate Institute for Medicine at firstname.lastname@example.org.